Product Images Abiraterone Acetate
View Photos of Packaging, Labels & Appearance
- 250 mg Abiraterone Acetate Tablet Blister - 250 mg Abiraterone Acetate Tablet Blister
- 250 mg Abiraterone Acetate Tablets Carton - 250 mg Abiraterone Acetate Tablets Carton
- AHP79021
- Figure 1: Kaplan-Meier Overall Survival Curves in COU-AA-301 (Intent-to-Treat Analysis) - Figure 1
- Figure 2: Kaplan Meier Overall Survival Curves in COU-AA-302 - Figure 2
- Figure 3: Kaplan Meier Curves of Radiographic Progression-free Survival in COU-AA-302 (Intent-to-Treat Analysis) - Figure 3
- Figure 4: Kaplan-Meier Plot of Overall Survival; Intent-to-treat Population in LATITUDE Updated Analysis - Figure 4
- Structural Formula - Structural Formula
Product Label Images
The following 8 images provide visual information about the product associated with Abiraterone Acetate NDC 60687-790 by American Health Packaging, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
250 mg Abiraterone Acetate Tablet Blister - 250 mg Abiraterone Acetate Tablet Blister
250 mg Abiraterone Acetate Tablets Carton - 250 mg Abiraterone Acetate Tablets Carton
This is information related to NDC 60667-790-21, which includes abiraterone acetate tablets in 30-tablet packaging. The tablets contain 250mg of Abiraterone Acetate, USP. A warning is issued to women who are pregnant or may become pregnant to avoid handling the tablets. The recommended dosage should be followed and the tablets should be swallowed whole without crushing or chewing. Storage instructions include keeping the product between 20°C to 25°C (68°F to 77°F). The product is distributed by American Health Packaging.*
AHP79021
Figure 1: Kaplan-Meier Overall Survival Curves in COU-AA-301 (Intent-to-Treat Analysis) - Figure 1
This text appears to be a table showing "Abiraterone Acetate" and "Placebo" options with corresponding numerical values indicating time to death in months. The values seem to be different over time intervals from 0 to 21 months for both options.*
Figure 2: Kaplan Meier Overall Survival Curves in COU-AA-302 - Figure 2
Figure 3: Kaplan Meier Curves of Radiographic Progression-free Survival in COU-AA-302 (Intent-to-Treat Analysis) - Figure 3
Figure 4: Kaplan-Meier Plot of Overall Survival; Intent-to-treat Population in LATITUDE Updated Analysis - Figure 4
This text appears to be a data table showing the survival of subjects without death in two groups: one group treated with Abiraterone acetate and the other with Placebo. The number of subjects at risk in each group is provided at various time points. The data seem to indicate a comparison of survival rates between the two groups over time.*
Structural Formula - Structural Formula
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
